Last update 01 Nov 2024

Zhejiang JinFang Pharmaceutical Co., Ltd.

Private Company|
2018|
Zhejiang Sheng, China

Overview

Tags

Neoplasms
Respiratory Diseases
Immune System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms4
Immune System Diseases3
Hemic and Lymphatic Diseases2
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug5
Top 5 TargetCount
BTK(Tyrosine-protein kinase BTK)1
CDK9(Cyclin-dependent kinase 9)1
ALK5(Transforming growth factor beta receptor 1)1
RIPK1(Receptor-interacting serine/threonine-protein kinase 1)1
KRAS G12C(GTPase KRas G12C)1

Related

6
Drugs associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
Fulzerasib
Target
KRAS G12C
Mechanism
KRAS G12C inhibitors
Active Org.
Zhejiang JinFang Pharmaceutical Co., Ltd. [+2]
Originator Org.
Genfleet Therapeutics (Shanghai), Inc.Genfleet Therapeutics (Shanghai), Inc.Startup
Active Indication
KRAS G12C mutant Non-small Cell Lung Cancer [+4]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CN
First Approval Date20 Aug 2024
Zanubrutinib
Target
BTK
Mechanism
BTK inhibitors
Active Org.
BeiGene Ltd.BeiGene Ltd. [+13]
Originator Org.
BeiGene Ltd.BeiGene Ltd.
Active Indication
Follicular Lymphoma [+31]
Inactive Indication
COVID-19 [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date14 Nov 2019
Tambiciclib
Target
CDK9
Mechanism
CDK9 inhibitors
Active Org.
Zhejiang JinFang Pharmaceutical Co., Ltd. [+2]
Originator Org.
Zhejiang JinFang Pharmaceutical Co., Ltd.
Active Indication
Acute Myeloid Leukemia [+6]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
20
Clinical Trials associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
NCT06375733 / RecruitingPhase 1/2
A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination With Zanubrutinib in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
CTR20240475 / RecruitingPhase 1/2
一项评价GFH009联合泽布替尼治疗复发或难治性弥漫性大B细胞淋巴瘤（DLBCL）患者安全性和有效性的单臂、开放、多中心Ib/II期临床试验
[Translation] A single-arm, open-label, multicenter Phase Ib/II clinical trial evaluating the safety and efficacy of GFH009 combined with zanubrutinib in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
CTR20231602 / RecruitingPhase 1/2
一项评估GFH009在复发或难治的外周T细胞淋巴瘤患者中的有效性、安全性/耐受性和药代动力学的多中心、开放标签、Ib/II期临床研究
[Translation] A multicenter, open-label, Phase Ib/II clinical study evaluating the efficacy, safety/tolerability, and pharmacokinetics of GFH009 in patients with relapsed or refractory peripheral T-cell lymphoma
100 Clinical Results associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
5
1
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free